PMID- 35450742
OWN - NLM
STAT- MEDLINE
DCOM- 20220920
LR  - 20220922
IS  - 0929-6646 (Print)
IS  - 0929-6646 (Linking)
VI  - 121
IP  - 10
DP  - 2022 Oct
TI  - Therapeutic efficacy and cognitive adverse events of overactive bladder 
      medication in patients with central nervous system Disorders-A cohort study.
PG  - 2101-2108
LID - S0929-6646(22)00147-4 [pii]
LID - 10.1016/j.jfma.2022.04.004 [doi]
AB  - PURPOSE: This cohort study evaluates therapeutic efficacy and adverse events 
      (AEs) of various overactive bladder (OAB) medications for patients with central 
      nervous system (CNS) disorders. METHODS: Patients with OAB and CNS disorders were 
      prospectively enrolled. They were randomly allocated to 3 different treatment 
      subgroups: (1) mirabegron 50 mg once daily (2) solifenacin 5 mg per day, and (3) 
      combined solifenacin 5 mg and mirabegron 50 mg once daily. Efficacy and safety 
      questionnaires and objective parameters were compared among the subgroups, and 
      subgroups between baseline and 3 and 6 months after treatment. AEs, including 
      cognitive dysfunction, were assessed using the Mini-Mental State Examination 
      (MMSE). RESULTS: 102 patients (mean age, 71.8 +/- 8.7 years) were enrolled, 
      including 35, 36, and 31 patients received mirabegron monotherapy, solifenacin 
      monotherapy, and combination therapy, respectively. OAB symptoms scores all 
      significantly improved 3 months after treatment in different subgroup. However, 
      PVR increased and VE decreased significantly after treatment in patients 
      receiving solifenacin monotherapy and combination therapy. Dry mouth and 
      constipation were the most common AEs, especially in the solifenacin and 
      combination subgroups. Mild incidence of AEs was noted in patients receiving 
      mirabegron monotherapy. No significant change in MMSE was noted among the 
      subgroups after treatment. CONCLUSION: OAB medication had good therapeutic 
      efficacy in patients who had OAB with CNS disorders, especially in 
      cerebrovascular accident and parkinsonism. No OAB medication or their combination 
      affected cognitive function, whereas minimal AEs were noted with mirabegron. 
      Mirabegron could be recommended as the first choice for managing OAB in these 
      patients.
CI  - Copyright (c) 2022 Formosan Medical Association. Published by Elsevier B.V. All 
      rights reserved.
FAU - Chen, Sheng-Fu
AU  - Chen SF
AD  - Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, 
      Hualien, Taiwan. Electronic address: madaux@yahoo.com.tw.
FAU - Chuang, Yao-Chi
AU  - Chuang YC
AD  - Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. 
      Electronic address: chuang82@ms26.hinet.net.
FAU - Wang, Chung-Cheng
AU  - Wang CC
AD  - Department of Urology, En Chu Kong Hospital, New Taipei City 23702, Taiwan. 
      Electronic address: ericwcc@ms27.hinet.net.
FAU - Liao, Chun-Hou
AU  - Liao CH
AD  - School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Division 
      of Urology, Department of Surgery, Cardinal Tien Hospital, New Taipei City, 
      Taiwan. Electronic address: liaoch0321@gmail.com.
FAU - Kuo, Hann-Chorng
AU  - Kuo HC
AD  - Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, 
      Hualien, Taiwan. Electronic address: hck@tzuchi.com.tw.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220418
PL  - Singapore
TA  - J Formos Med Assoc
JT  - Journal of the Formosan Medical Association = Taiwan yi zhi
JID - 9214933
RN  - 0 (Acetanilides)
RN  - 0 (Thiazoles)
RN  - 0 (Urological Agents)
RN  - KKA5DLD701 (Solifenacin Succinate)
RN  - MVR3JL3B2V (mirabegron)
SB  - IM
MH  - Acetanilides/adverse effects
MH  - Aged
MH  - Aged, 80 and over
MH  - *Central Nervous System Diseases/complications/drug therapy
MH  - Cognition
MH  - Cohort Studies
MH  - Drug Therapy, Combination/adverse effects
MH  - Humans
MH  - Middle Aged
MH  - Solifenacin Succinate/adverse effects
MH  - Thiazoles/adverse effects
MH  - Treatment Outcome
MH  - *Urinary Bladder, Overactive/drug therapy
MH  - *Urological Agents/adverse effects
OTO - NOTNLM
OT  - Antimuscarinics
OT  - Central nervous system
OT  - Cognitive impairment
OT  - Mirabegron
OT  - Overactive bladder
COIS- Declaration of competing interest The authors have no conflicts of interest 
      relevant to this article.
EDAT- 2022/04/23 06:00
MHDA- 2022/09/21 06:00
CRDT- 2022/04/22 07:03
PHST- 2021/12/02 00:00 [received]
PHST- 2022/03/03 00:00 [revised]
PHST- 2022/04/07 00:00 [accepted]
PHST- 2022/04/23 06:00 [pubmed]
PHST- 2022/09/21 06:00 [medline]
PHST- 2022/04/22 07:03 [entrez]
AID - S0929-6646(22)00147-4 [pii]
AID - 10.1016/j.jfma.2022.04.004 [doi]
PST - ppublish
SO  - J Formos Med Assoc. 2022 Oct;121(10):2101-2108. doi: 10.1016/j.jfma.2022.04.004. 
      Epub 2022 Apr 18.